

**Confidential Attorney-Client
Privileged Communication**

Amendments to the Claims

The following listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently amended) A liquid pharmaceutical composition comprising (i) levocetirizine or a pharmaceutically acceptable salt of levocetirizine, and (ii) ~~at least one preservative, wherein the preservative is a preservative mixture consisting essentially of a mixture of methyl parahydroxybenzoate and propyl parahydroxybenzoate in a ratio of 9/1 expressed in weight, said mixture being present in an amount of more than 0 and less than 1.125 mg/ml of the composition, wherein said composition is substantially free of bacteria.~~
2. (Previously presented) The liquid pharmaceutical composition according to claim 1, wherein the composition is aqueous.
3. (Canceled)
4. (Canceled)
5. (Previously presented) The liquid pharmaceutical composition according to claim 1, wherein the amount of the p-hydroxybenzoate esters is in the range of 0.0001 and 1 mg/ml of the composition.
6. (Canceled)
7. (Canceled)
8. (Canceled)
9. (Canceled)
10. (Canceled)
11. (Canceled)
12. (Previously presented) The liquid pharmaceutical composition according to claim 1, wherein the composition is in the form of oral solutions, nasal drops, eye drops or ear drops.

**Confidential Attorney-Client
Privileged Communication**

13. (Canceled)
14. (Currently amended) The liquid pharmaceutical composition according to claim ~~13~~ 1, wherein the pharmaceutically acceptable salt of levocetirizine is a hydrochloride salt.
15. (Previously Presented) The liquid pharmaceutical composition according to claim 14, wherein the hydrochloride salt of levocetirizine is present in amount of 0.5 mg/ml and the mixture of methyl p-hydroxybenzoate and propyl p-hydroxybenzoate is present in amount of 0.75 mg/ml.
16. (Canceled)
17. (Previously presented) The liquid pharmaceutical composition according to claim 1, which composition comprises levocetirizine or a pharmaceutically acceptable salt that is at least 95% by weight of the levorotatory enantiomer of cetirizine.
18. (Withdrawn-previously presented) A method of making a liquid pharmaceutical composition according to claim 1 comprising combining,
 - a) cetirizine, levocetirizine, efletirizine, or a pharmaceutically acceptable salt of cetirizine, levocetirizine, or efletirizine, and
 - b) parahydroxybenzoate ester in an amount of more than 0 and less than 1 mg/ml of the composition.
19. (Withdrawn) The method according to claim 18, comprising mixing levocetirizine or a pharmaceutically acceptable salt thereof with a mixture of methyl p-hydroxybenzoate and propyl p-hydroxybenzoate.
20. (Withdrawn) The method according to claim 19, comprising mixing a pharmaceutically acceptable salt of levocetirizine with a mixture of methyl p-hydroxybenzoate and propyl p-hydroxybenzoate, wherein the methyl p-hydroxybenzoate and propyl p-hydroxybenzoate are present in a ratio of 9:1.
21. (Withdrawn) The method according to claim 20, wherein the pharmaceutically acceptable salt of levocetirizine is a hydrochloride salt.

**Confidential Attorney-Client
Privileged Communication**

22. (Withdrawn) In a method of treating a patient with cetirizine, levocetirizine, efletirizine, or a pharmaceutically acceptable salt of cetirizine, levocetirizine, or efletirizine, the improvement comprising administering a liquid composition according to claim 1.
23. (Withdrawn) The method according to claim 23, wherein the liquid composition comprises levocetirizine or a pharmaceutically acceptable salt thereof and a mixture of methyl p-hydroxybenzoate and propyl p-hydroxybenzoate.
24. (Withdrawn) The method according to claim 23, wherein the pharmaceutically acceptable salt of levocetirizine is a hydrochloride salt.
25. (Withdrawn) The method according to claim 24, wherein the hydrochloride salt of levocetirizine is present in amount of 0.5 mg/ml and the mixture of methyl p-hydroxybenzoate and propyl p-hydroxybenzoate is present in amount of 0.75 mg/ml.
26. (Withdrawn) The method according to claim 25, wherein the methyl p-hydroxybenzoate and propyl p-hydroxybenzoate are present in a ratio of 9:1 by weight.
27. (Previously presented) The liquid pharmaceutical composition according to claim 1, wherein the mixture of methyl parahydroxybenzoate and propyl parahydroxybenzoate is present in an amount of more than 0 and less than 1 mg/ml of the composition.
28. (New) The composition of claim 1, wherein the composition is in the form of an oral solution comprising 0.50 mg/ml levocetirizine dihydrochloride, 0.675 mg/ml methyl p-hydroxybenzoate, and 0.075 mg/ml propyl p-hydroxybenzoate.
29. (New) The composition of claim 1, wherein the composition is in the form of a solution of oral drops comprising 5.0 mg/ml levocetirizine dihydrochloride, 0.3375 mg/ml methyl p-hydroxybenzoate, and 0.0375 mg/ml propyl p-hydroxybenzoate.